There are huge efforts to find effective therapies for COVID-19 infection. Numerous trials are in progress; indeed, more than 1000 studies addressing various aspects of COVID-19 were found to be registered on [ClinicalTrials.gov](http://ClinicalTrials.gov){#ir0005} on 15 May 2020, including more than 600 interventional studies and randomized clinical trials (RCTs) \[[@bb0005]\].

The collection and clinical use of COVID-19 convalescent plasma (CCP) is under development and early use in many centers and countries. Those implementing CCP are likely to prepare and administer it in different ways. This variation is not surprising given the urgency of the situation, and the limited evidence base for the safety and effectiveness of convalescent plasma against the several infectious agents against which it has been used \[[@bb0010],[@bb0015]\].

There are several key questions surrounding the use of CCP as a therapeutic. These include antibody testing and donor selection, methods of collection and storage, dose and duration of treatment, lot to lot variability, adverse effects, selection of the patients most likely to benefit, and measurement of efficacy. A number of publications have already addressed some of these issues and a few have provided either recommendations \[[@bb0015], [@bb0020], [@bb0025], [@bb0030], [@bb0035], [@bb0040]\] or preliminary results \[[@bb0045]\]. Links to some websites providing information and/or recommendations about CCP are provided in [Appendix 1](#ec0005){ref-type="supplementary-material"}.

There are several key questions surrounding the use of CCP as a therapeutic. These include antibody testing and donor selection, methods of collection and storage, dose and duration of treatment, lot to lot variability, adverse effects, selection of the patients most likely to benefit, and measurement of efficacy. A number of publications have already addressed some of these issues and a few have provided either recommendations \[[@bb0015], [@bb0020], [@bb0025], [@bb0030], [@bb0035], [@bb0040]\] or preliminary results \[[@bb0045]\]. Links to some websites providing information and/or recommendations about CCP are provided in Appendix 1.

Before being offered for routine use, this new intervention should be rigorously tested in clinical trials designed to define both safety and efficacy. This leads to questions about the design and conduct of these trials so that valid data are provided for analysis as quickly as possible. If CCP is found to be safe and effective, the lessons learned from the trials about the optimal methods for preparing and administering CCP will need to be implemented as a matter of urgency.

We report the results of an international survey of centers undertaking early studies of CCP to provide an understanding of the common themes and differences between them in the preparation and investigation of CCP and that by virtue of their design some studies may be more informative than others.

Methods {#s0005}
=======

A survey tool was developed to collect information from centers planning to collect and administer CCP to patients with COVID-19 infection. The centers were identified on 1st May 2020 from a search of [Clinicaltrials.gov](http://Clinicaltrials.gov){#ir0010}, the Chinese Clinical Trial Registry (ChiCTR) and personal contacts of the authors. The survey tool was written in English and designed to gather information on the whole process of the collection and administration of CCP from the identification of suitable donors including antibody testing, through the collection and storage of the product, the identification of patients suitable for its administration and details of the design of clinical trials. We did not ask about the planned completion dates of the studies so it is not known when the results will be available.

Results {#s0010}
=======

The survey was sent electronically to the study contacts for 64 studies in 22 countries shown in [Fig. 1](#f0005){ref-type="fig"} and listed in [Appendix 2](#ec0010){ref-type="supplementary-material"} with a request to complete and return it within 7 days. We received responses from 20 of 64 (31%) studies from 12 of 22 (55%) countries, and they provide the data for this report.

The first survey questions were about the design of the studies. Of the 20 studies, 11 were randomized controlled trials (RCTs) and 9 were case series ([Table 1A](#t0005){ref-type="table"} ). There was blinding of the investigators to the intervention in 3 of 11 RCTs where standard plasma was used as a comparator, and no blinding in the other 8. Among the RCTs, there was huge variation in the number of study sites (range, 1-250), and this was even more marked in the non-RCTs (range, 1-1300+). There was also considerable variation in the number of patients receiving CCP in both the RCTs (range, 40-5000) and in the case series (6-10 000).Fig. 1World map showing the number of CCP studies and the confirmed number of cases of COVID-19 by country as of May 15, 2020.Fig. 1Table 1AStudy design.Table 1AStudy identifierDesignNumber of study sitesNumber of patients receiving CCPAge of patients (years)Upper age limitUSA 1Case series1300+10 000\>18NoUSA 2RCT (blinded)1--10103\>18NoUSA 3RCT (blinded)1400\>18NoUSA 4Case series130\>18NoUSA 5Case series20100AdultsNoUSA 6RCT (blinded)2--10110\>18NoChina 1Case series16Not statedNoMexico 1Case series110\>18NoSpain 1RCT (un-blinded)25139Not statedNoSpain 2RCT (un-blinded)16018--6969Canada 1RCT (un-blinded)53800≥16NoCanada 2RCT (un-blinded)161000--1818Iran 1Case series13030--7070UK 1RCT (un-blinded)1201000\>18NoUK 2RCT (un-blinded)2505000\>0NoEgypt 1Case series140\>18NoFrance 1RCT (un-blinded)960\>18NoGermany 1RCT (un-blinded)140\<7575Saudi Arabia 1Case series1740\>18NoSwitzerland 1Case series11018--7575[^1]

The comparison intervention to CCP was standard plasma in 3 of 11 RCTs, and no plasma in the others (although not stated in one study) ([Table 1B](#t0010){ref-type="table"} ). The clinical stages of illness targeted by the different trials are shown in [Fig. 2](#f0010){ref-type="fig"} . Most RCTs (9/11) included symptomatic, infected but not critically ill patients; 6 RCTs included critically ill patients; and 2 included asymptomatic infected patients. In contrast, all but one of the case series included critically ill patients. None of the studies focused on non-infected at risk individuals. Children were included as study participants in 3 of the RCTs. All studies required a positive PCR test of the recipient except for one of the studies in Iran (Iran-1) and the study in France. The collection of possible adverse effects was similar for all studies, although only 4 studies specifically included antibody dependent enhancement of infection (ADE).Table 1BStudy design (continued)Table 1BStudy identifierComparison group for the RCTsExclusionsAdverse effectsUSA 1Non-randomized patientsNoneFebrile, allergic, anaphylaxis; TACOUSA 2Standard plasmaAdmission to hospital for ventilationAnaphylaxis; TACO, TRALI; TTIUSA 3Standard plasmaPregnancyFebrile, allergic, anaphylaxis;TACOUSA 4Non-randomized patientsVentilator dependentNot statedUSA 5Non-randomized patientsNoneFebrile, allergic, anaphylaxis;TACO, TRALIUSA 6Standard plasmaCardiac or respiratory failure; Participation in other trialsFebrile, allergic, anaphylaxis;TACOChina 1Non-randomized patientsPregnancyFebrile, allergic, anaphylaxis;TACOMexico 1Non-randomized patientsRenal failure; ECMO; PregnancyFebrile, allergic, anaphylaxis;TACOSpain 1Not statedSymptoms \>12 days prior; Ventilator or high flow O~2;~ Renal failure; Participation in other trialsFebrile, allergic, anaphylaxis;TACO, TRALI; ADESpain 2No plasmaParticipation in other trialsFebrile, allergic, anaphylaxis;TACOCanada 1No plasmaVentilator or ECMO; Symptoms \>12 days priorFebrile, allergic, anaphylaxis;TACOCanada 2No plasmaNot statedFebrile, allergic, anaphylaxis; TACOIran 1Non-randomized patientsPre-intubation; Ventilator dependent;Not statedHeart failureUK 1No plasmaParticipation in other trialsFebrile, allergic, anaphylaxis; TACO, TRALI, TAD; ADE; ThrombosisUK 2No plasmaParticipation in other trialsFebrile, allergic, anaphylaxis; TACO, TRALI; ADEEgypt 1Non-randomized patientsVentilator or ECMO; Cardiac, pulmonary, renal, or liver failure;Not defined at time of surveyParticipation in other trialsFrance 1No plasmaVentilator or ECMO; Cardiac, pulmonary, renal, or liver failure;Febrile, allergic, anaphylaxis; TACO; ADEPregnancy; Uncontrolled infection;Participation in other trialsGermany 1No plasmaLiver failure; Pregnancy; Participation in other trialsFebrile, allergic, anaphylaxis; TACOSaudi Arabia 1Non-randomized patientsNot defined at time of surveyTransfusion reactions per aaBBSwitzerland 1Non-randomized patientsVentilator or ECMO; Cardiac, pulmonary failure; Pregnancy;Febrile, allergic, anaphylaxis; TACO; Other adverse eventsParticipation in other trials[^2][^3][^4]Fig. 2Study enrolment according to clinical stage of disease based on survey responses. The number in parentheses is the number of subjects planned to receive CCP. The shaded boxes indicate randomized controlled trials.Fig. 2

There was considerable variability in the primary and secondary outcomes for the studies ([Table 2](#t0015){ref-type="table"} ). [Fig. 3](#f0015){ref-type="fig"} provides a summary of the primary outcomes with the most frequent being clinical change and mortality. The primary outcomes for the 3 largest RCTs were a composite of intubation or death at day 30 (USA-6), ventilation-free days (Canada-1) and mortality at 28 days (UK-2).Table 2Primary and secondary outcomesTable 2Study identifierPrimary outcomeMain secondary outcomesUSA 1Availability of convalescent plasmaSerious adverse eventsUSA 2Time to progression using outpatient ordinal scaleNot recordedUSA 3Days on ventilationMortality at day 90USA 4Feasibility of treating ICU patientsNot recordedUSA 5Not yet decidedDays on ventilation; LOS in ICU; Hospital LOSUSA 6Modified WHO score at day 14Days on ventilation; Hospital LOS;\
Change in viral load; Mortality at day 28China 1Change in viral loadDays on ventilationMexico 1Change in lung injury (Kirby index)Mortality at day 15 & 30Spain 1Proportion in level 5 or higher of 7-level ordinal scaleDays on ventilation; Hospital LOS;\
Change in viral load; Time to clinical worsening;\
Mortality at 15 daysSpain 2Feasibility and safety (pilot study)Days on ventilation; LOS in ICUCanada 1Composite of intubation or death at day 30Days on ventilation; LOS in ICU; Hospital LOS;\
Change in viral loadCanada 2Time to recovery or discharge by day 30LOS in ICU; Hospital LOS; Change in viral load;\
Others not specifiedIran 1Mortality at days 10 & 30Days on ventilation; Hospital LOS;\
Changes to laboratory tests at day 1, 3 & 7UK 1Ventilator-free days at day 21Days on ventilation; Hospital LOS; Change in viral load; Level of respiratory support at day 15UK 2Mortality (date not yet specified)Days on ventilation; LOS in ICU; Hospital LOS;\
Renal impairmentEgypt 1LOS in ICUHospital LOSFrance 1Ventilation-free survival at day 14Days on ventilation; LOS in ICU; Hospital LOS;\
Disease severity (WHO scale) at day 7 & 14Germany 1Mortality at day 28Days on ventilation; LOS in ICU; Hospital LOS;\
Change in viral loadSaudi Arabia 1LOS in ICUDays on ventilation; Days to clinical recoverySwitzerland 1Immune markers before vs after infusionClinical change (7-point ordinal scale);\
serious adverse events[^5]Fig. 3Primary outcomes of CCP trials based on survey responses.Fig. 3

The donor eligibility criteria for the collection of CCP were very similar among the studies ([Table 3](#t0020){ref-type="table"} ). In 15 of 16 studies where this information was provided, the respondents indicated the requirement for a prior positive polymerase chain reaction (PCR) assay for SARS-COV2. The time required from recovery of symptoms of COVID-19 infection before collection of CCP varied from 14 to 28 days. Nearly all studies indicated that female donors would be tested for HLA or HLA and HNA antibodies to minimize the risk of transfusion-related acute lung injury (TRALI). Plasmapheresis was selected as the method of collection of CCP by nearly all investigators.Table 3Donor eligibilityTable 3Study identifierDonor categoryPrior SARS-CoV2 in donorOther donor qualificationsMethod of collectionUSA 1UncertainNot statedNot statedNot statedUSA 2Males; Females negative for HLA antibodiesPositive PCRNeg PCR if 14--28 days;Plasmapheresis≥ 28 d after symptomsUSA 3Males; Females negative for HLA & HNA antibodiesPositive PCR or antibody≥ 14 d after symptomsPlasmapheresisUSA 4Males; Females negative for HLA & HNA antibodiesPositive PCR≥ 14 d after symptomsPlasmapheresisUSA 5Males; Females negative for HLA & HNA antibodiesPositive PCR≥ 28 d after symptomsPlasmapheresisUSA 6Males; Females negative for HLA antibodiesPositive PCRNeg PCR if 14--28 days;Plasmapheresis≥ 28 d after symptomsChina 1Males; Females negative for HLA & HNA antibodiesPositive PCR≥ 14 d after symptomsNot statedMexico 1Males; Females negative for HLA antibodiesPositive PCR≥ 14 d after symptomsMainly plasmapheresisSpain 1Not statedNot statedNot statedNot statedSpain 2Males; Females negative for HLA & HNA antibodiesPositive PCR≥ 14 d after symptomsPlasmapheresisCanada 1Males; Females negative for HLA antibodiesPositive PCRNeg PCR if 14--28 days;Plasmapheresis≥ 28 d after symptomsCanada 2Males; Females negative for HLA & HNA antibodiesPositive PCR≥ 28 d after symptoms (Canadian Blood Services);Plasmapheresis≥ 14 d after symptoms (HemaQuebec)Iran 1Not statedNot statedRecovery from illnessNot statedUK 1Males; Females negative for HLA & HNA antibodiesPositive PCR plus antibody≥ 28 d after symptomsMainly plasmapheresisUK 2Males; Females negative for HLA & HNA antibodiesPositive PCR plus antibody≥ 28 d after symptomsMainly plasmapheresisEgypt 1Male donors onlyPositive PCR≥ 14 d after symptomsPlasmapheresisFrance 1Males; Females negative for HLA antibodiesClinical illness test not required≥ 14 d after symptomsPlasmapheresisGermany 1UncertainUncertain at time of surveyNot statedPlasmapheresisSaudi Arabia 1Males; Females negative for HLA antibodiesPositive PCR≥ 14 d after negative PCRPlasmapheresisSwitzerland 1Male donors onlyPositive PCR≥ 28 d after symptomsPlasmapheresis[^6]

The dose of plasma was 400 to 800 mL or 4 mL/kg or greater in all 10 RCTs and in 6 of 8 of the case series providing this information ([Table 4](#t0025){ref-type="table"} ). Protocols called for CCP to be stored in the frozen state prior to thawing before administration in all 16 studies that provided this information apart from one study (Germany-1). Six studies including only 2 of the RCTs indicated that the CCP would be pathogen-inactivated.Table 4Details of plasma dosingTable 4Study identifierDose (mL)Number of infusionsControl plasma detailsStorage conditions of CCPPathogen inactivationUSA 1200--5001No control plasma\
(case series)Not statedNot statedUSA 24--6 mL/kg[⁎](#tf0005){ref-type="table-fn"}1Given prior to dischargeFrozen then thawedNoUSA 35001Low antibody for SARS-CoV2Frozen then thawedUncertain at time of surveyUSA 440 mL/kg1No control plasma\
(case series)Not statedNot statedUSA 5200--5001No control plasma\
(case series)Frozen then thawedNoUSA 65002 (day 1 and 2)2 doses of FFP or FP24Frozen then thawedNoChina 1200Depends on availabilityNo control plasma\
(case series)Frozen then thawedYesMexico 12001No control plasma\
(case series)Frozen then thawedNoSpain 1Not statedNot statedNot statedNot statedNot statedSpain 2600\
(200 × 3)Every 8 h up to 3 dosesNo control plasma (unblinded)Frozen then thawedMethylene blue or amotosalenCanada 1500 (250 x2)1No control plasma (unblinded)Frozen then thawedNoCanada 210 mL/kg\
(500 max)1No control plasma (unblinded)Frozen then thawedUncertain at time of surveyIran 1Not statedNot statedNot stated\
(case series)Not statedNot statedUK 1400--700\
(200--300 × 2)2 (day 1 and 2)No control plasma (unblinded)Frozen then thawedNoUK 2400--700\
(200--300 × 2)2 (day 1 and 2)No control plasma (unblinded)Frozen then thawedNoEgypt 1400--5001No control plasma\
(case series)Frozen then thawedMixtureFrance 1800--880\
(400--440 × 2)2 (day 1 and 2)No control plasma (unblinded)Frozen then thawedYesGermany 14001No control plasma (unblinded)Stored at 4C (not frozen)NoSaudi Arabia 1200--400Daily up to 5 timesNo control plasma\
(case series)Frozen then thawedYesSwitzerland 1600\
(200 × 3)3No control plasma\
(case series)Frozen then thawedYes[^7]

Responses were received to questions about donor antibody testing from 15 of 20 of survey participants ([Table 5](#t0030){ref-type="table"} ). Eleven of 15 of all studies and 8 of 11 of the RCTs indicated that antibody testing would be carried out before the administration of CCP, and the remainder after its administration. Eleven of 15 of all studies and 6 of 11 of the RCTs indicated that testing would include neutralizing antibodies sometimes with additional testing for non-neutralizing antibodies. Only 8 studies provided information about cut-off levels or titers of antibodies used to qualify donors.Table 5Antibody testing of donorTable 5Study identifierDonor antibody testing before or after infusionAntibody test detailsUSA 1Not statedNot statedUSA 2BeforeNon-neutralizing titer \>1:80USA 3BeforeNon-neutralizing per FDA guidelinesUSA 4Uncertain at time of surveyUncertain at time of surveyUSA 5BeforeNeutralizing antibody \>1:100 (Euroimmune)USA 6BeforeNeutralizing plus non-neutralizing \>1:160China 1BeforeNon-neutralizing \>1:160Mexico 1AfterNeutralizing plus non-neutralizing (no cut-off)Spain 1Not statedNot statedSpain 2BeforeNon-neutralizing EIA O.D. \>1.0Canada 1BeforeNeutralizing antibody \>1:160 or EIACanada 2AfterNeutralizing plus non-neutralizing (cut-off not decided)Iran 1Not statedNot statedUK 1BeforeNeutralizing plus non-neutralizing (cut-off not decided)UK 2BeforeNeutralizing plus non-neutralizing (cut-off not decided)Egypt 1AfterNeutralizing antibody \>1:40France 1BeforeNeutralizing \>1:30 plus non-neutralizingGermany 1Uncertain at time of surveyUncertain at time of surveySaudi Arabia 1BeforeNeutralizing plus non-neutralizing (no cut-off)Switzerland 1AfterNeutralizing plus non-neutralizing (no cut-off)

Discussion {#s0015}
==========

The COVID-19 pandemic represents a major threat to global health and has caused enormous strain on healthcare systems worldwide. One of the major research challenges is to develop trials to determine the effectiveness of any promising therapies, and one of these treatment options is CCP. A systematic review has shown that convalescent plasma (CP) may have clinical benefit for people with acute viral diseases such as influenza and severe acute respiratory syndrome (SARS) \[[@bb0050]\], but its effectiveness in patients with COVID-19 is as yet uncertain \[[@bb0040]\]. One reason for this is that many outbreaks are regional and short-lived not providing sufficient time to collect and carefully study the safety and efficacy of CP. The current COVID-19 pandemic may not be bound by such limitations and there is likely to be sufficient time to collect CCP to treat newly infected patients. The logical first research questions are to determine the safety and effectiveness of CCP; and not surprisingly, numerous studies have been established to do this worldwide. We have undertaken an international survey of centers who have instituted studies of CCP to provide an understanding of the similarities and differences between them.

We identified 64 CCP studies in 22 countries by searching trial registries and through personal contacts. This probably represents an unprecedented upsurge in studies of any single topic in transfusion medicine. We recognize that we may not have identified all CCP studies, and that further studies will have been initiated since we began the survey. We contacted those we identified as the principal investigators by email requesting rapid completion of the survey and received 20 responses from 64 studies (31%) from 12 of 22 countries (55%).

The responses raise concerns about their ability to determine the effectiveness of CCP across the clinical spectrum of COVID-19 infected patients. These concerns include the lack of randomization in 11 of 20 studies and small sample size in 10 of 20. Only 4 of the RCTs plan to recruit 400 patients or more so that the majority of studies are unlikely to have sufficient power to detect significant changes in key outcomes. A substantial proportion of survey respondents noted that mortality would be a primary outcome. Current estimates would suggest that the mortality rate of among hospitalized patients is approximately 15%, and in order to detect a 10% relative reduction in death rate (from 15% to 13.5%) with 80% power and alpha = 0.05 would require a study with over 15 000 participants. Furthermore, 8 RCTs are unblinded which may introduce bias in the assessment of outcomes other than mortality. On the other hand, the 3 blinded RCTs, where standard plasma is being used as the comparator to CCP, may have a reduced ability to detect harms from the transfusion of plasma in COVID-19 infected patients. Among those who responded to the survey, the majority of studies place emphasis on the effect of CCP on sick patients requiring hospitalization and those requiring critical care, and none is examining the role of CCP in non-infected at-risk individuals. A wide variety of primary and secondary outcomes were selected by investigators which likely reflects uncertainty regarding the most appropriate study outcome for CCP at different stages of COVID-19 infection.

The donor eligibility criteria for the collection of CCP are very similar among the studies in the almost universal requirement for a prior positive PCR assay for SARS-COV2 although there is variation in the time from recovery of symptoms of COVID-19 infection before collection of CCP. Nearly all survey respondents plan to use plasmapheresis to collect CCP and only some plan to use pathogen-inactivation. The planned dose of CCP ranges from as little as 200 mL to well over 1 L, but is 400 to 800 mL or 4 mL/kg or greater in all the RCTs. There is considerable variability in donor antibody testing with testing for neutralizing antibodies or non-neutralizing antibodies alone, or a combination of the two; and there is no consistency regarding the cut-off for antibody titer for acceptance as CCP or the use of pathogen-inactivation. Individual units of CCP would be expected to have a range of viral neutralizing capacity depending on their characteristics such as the dose, antibody titer, and antibody affinity, thereby further complicating inferences about efficacy.

As shown in [Appendix 2](#ec0010){ref-type="supplementary-material"}, a large number of studies of CCP are planned worldwide. Our survey provides an informative sampling of these and indicates shared similarities and differences among them. By virtue of randomization, blinding, and sample size some studies may be more informative than others. The survey clearly shows an initial focus on sick hospitalized patients. Whether passive transfer of antibody may prove to be more effective in very recently infected individuals or non-infected persons at high risk for infection will await other studies not represented here. Results of all well-designed trials are eagerly awaited. The COVID-19 pandemic provides the first opportunity in history to rigorously define the role of convalescent plasma in a critically important viral respiratory disease.

The following are the supplementary data related to this article.Appendix 1Useful links to sites providing information and/or recommendations about CCP.Appendix 1 Appendix 2CCP studies identified by May 1, 2020. Survey responses were received from those studies shown in shading.Appendix 2
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[^1]: RCT, randomized control trial.

[^2]: 'No plasma' indicates no infusion of any fluid.

[^3]: TACO, transfusion associated circulatory overload; TRALI, transfusion related acute lung injury; TTI, transfusion transmitted infection; ADE, antibody dependent enhancement of infection; TAD, transfusion associated dyspnea; aaBB, American Association of Blood Banks.

[^4]: All studies require a positive PCR test of the recipient except France-1 and Iran-1.

[^5]: ICU, intensive care unit; LOS, length of stay.

[^6]: PCR, polymerase chain reaction.

[^7]: Ideal body weight.
